Recently, CD147 was identified as a receptor mediating the entry of SARS-CoV-2 and its variants into host cells.26–28 In this work, virus inhibition experiments were performed using CD147 antibody (meplazumab), which showed that low concentration of meplazumab effectively suppressed the infection of Omicron, and further mitigated cytokine release storm. This evidence concerns the gene BSG and infection.